Long-term safety of tegoprubart in kidney transplant patients
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This is a long-term follow-up study for people who have already completed a study of the drug tegoprubart after a kidney transplant. It checks how safe and effective the drug is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed an earlier (parent) study that offered you the chance to join this long-term follow-up.
- You must be able to understand the study information and agree to the consent form.
- You must agree not to take part in any other research study while on this treatment.
- If you could become pregnant, you need a negative pregnancy test before starting and must use effective birth control during and for 90 days after the last dose.
- If you are a man with a partner who could become pregnant, you must use effective birth control and not donate sperm for 90 days after the last dose.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new medicine called tegoprubart with a standard medicine called tacrolimus for people who are getting a kidney transplant. The goal is to see if the new medicine is safe and works as well as or better than the standard one to keep the new kidney healthy.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
This study checks the long-term safety of felzartamab for people who have had a kidney transplant and are dealing with antibody-mediated rejection or signs of inflammation in the kidney. It's for those who were already in a previous study and took at least one dose of felzartamab.
This Phase 1/2 trial tests how safe AT 1501 is and how it works in people getting their first kidney transplant. It aims to improve transplant outcomes by targeting the immune system, while carefully watching for side effects and immune compatibility issues.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This study looks at different treatments for a type of kidney transplant rejection called antibody-mediated rejection, where the body's immune system attacks the new kidney. It aims to understand how these treatments work and how they might help people keep their transplanted kidney healthy.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.